There’s a reason that venture firms in Boston love building their own companies: It helps to have a hand-picked leader with a proven track record at the helm of an early-stage biotech company.
Waltham, Mass.-based Skyhawk Therapeutics is bucking that trend with gusto. In June 2018, the company announced a $100 million early-stage venture fundraising round and partnership deals with Biogen and Celgene (which was just acquired by Bristol-Myers Squibb for $74 billion). Earlier this month, the company was at the annual J.P. Morgan Healthcare Conference looking for more. Yet their chief executive officer, Bill Haney, has less than five years of experience as a biotech executive; his only other biotech company is Dragonfly Therapeutics.
About the Author Reprints
Well, it seems like you will never be as good at convincing investors of anything, but rather sound like a complete tool who thinks he is owed something. And as to your credentials, you can shove them. Credentials don’t equal creativity… tool.
Fun fact:
neither the CEO/co-founder, nor the CSO/co-founder have either an MD and/or a PhD degree. They must be so good they didn’t need one. Even more so, by claiming they are creating innovative treatments.
I wish I was as good as them at convincing investors despite not having adequate scientific credentials. Maybe, that’s the problem, I actually have proper scientific credentials.